

Clinical Policy: Decitabine/Cedazuridine (Inqovi)

Reference Number: CP.PHAR.479

Effective Date: 07.07.20

Last Review Date: 05.26

Line of Business: Commercial, HIM/ICHRA, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

Description

Decitabine/cedazuridine (Inqovi[®]) is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor.

FDA Approved Indication(s)

Inqovi is indicated:

- For treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
- In combination with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with Centene Corporation[®] that Inqovi is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Myelodysplastic Syndromes (must meet all):

1. Diagnosis of MDS;
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age \geq 18 years;
4. Member must use decitabine[^], unless one of the following applies (a or b):*
 - a. Decitabine is contraindicated or clinically significant adverse effects are experienced;
 - b. Request is for treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (*see Appendix E*);

[^]Prior authorization may be required for decitabine

*For Illinois HIM requests, the step therapy requirements above do not apply as of 1/1/2026 per IL HB 5395

5. Request meets one of the following (a or b):*
 - a. Dose does not exceed 35 mg decitabine/100 mg cedazuridine (1 tablet) per day on Days 1 through 5 of each 28-day cycle;
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration:

Medicaid/HIM/ICHRA– 12 months

Commercial – 12 months or duration of request, whichever is less

B. Acute Myeloid Leukemia (must meet all):

1. Diagnosis of AML;
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age \geq 18 years;
4. One of the following (a or b):
 - a. Age \geq 75 years and disease is newly diagnosed;
 - b. Member is not a candidate for or declines use of intensive induction chemotherapy (*see Appendix D for examples*);
5. Member must use decitabine[^], unless one of the following applies (a or b):*
 - a. Decitabine is contraindicated or clinically significant adverse effects are experienced;
 - b. Request is for treatment associated with cancer for a State with regulations against step therapy in certain oncology settings (*see Appendix E*);

[^]*Prior authorization may be required for decitabine*

**For Illinois HIM requests, the step therapy requirements above do not apply per IL HB 5395*

6. Prescribed in combination with venetoclax (Venclexta[®]);*
**Prior authorization may be required*
7. Request meets one of the following (a or b):*
 - a. Dose does not exceed 35 mg decitabine/100 mg cedazuridine (1 tablet) per day on Days 1 through 5 of each 28-day cycle;
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration:

Medicaid/HIM/ICHRA– 12 months

Commercial – 12 months or duration of request, whichever is less

C. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the

- relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

II. Continued Therapy

A. All Indications in Section I (must meet all):

1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving Inqovi for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):*
 - a. New dose does not exceed 35 mg decitabine/100 mg cedazuridine (1 tablet) per day on Days 1 through 5 of each 28-day cycle;
 - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*Prescribed regimen must be FDA-approved or recommended by NCCN.

Approval duration:

Medicaid/HIM/ICHRA– 12 months

Commercial – 12 months or duration of request, whichever is less

B. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to one of the following policies (a or b):
 - a. For drugs on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the no coverage criteria policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.33 for health insurance marketplace/ICHRA, and CP.PMN.255 for Medicaid; or
 - b. For drugs NOT on the formulary (commercial, health insurance marketplace/ICHRA) or PDL (Medicaid), the non-formulary policy for the relevant line of business: CP.CPA.190 for commercial, HIM.PA.103 for health insurance marketplace/ICHRA, and CP.PMN.16 for Medicaid; or
2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy for the relevant line of business: CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policies –

CP.CPA.09 for commercial, HIM.PA.154 for health insurance marketplace/ICHRA, and CP.PMN.53 for Medicaid or evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

AML: acute myeloid leukemia
 CMML: chronic myelomonocytic leukemia
 FDA: Food and Drug Administration
 MDS: myelodysplastic syndrome
 NCCN: National Comprehensive Cancer Network

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
decitabine	<p>MDS</p> <p><u>Three day regimen:</u> 15 mg/m² by IV infusion every 8 hours for 3 days. Repeat cycle every 6 weeks.</p> <p><u>Five day regimen:</u> 20 mg/m² by IV infusion repeated daily for 5 days. Repeat cycle every 4 weeks.</p> <p>AML</p> <p>20 mg/m² by IV infusion repeated daily for Days 1-5 of each 28-day cycle.</p>	See regimens

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

None reported

Appendix D: General Information

Patient or disease state characteristics that may preclude use of intensive induction therapy include but are not limited to the following examples:

- Limited functional status as indicated by an Eastern Cooperative Oncology Group (ECOG) performance status of ≥ 2
- Significant comorbidity (e.g., severe cardiac, pulmonary, or renal disease)
- AML without favorable cytogenetics or molecular markers
- AML secondary to prior antineoplastic therapy
- AML preceded by a hematologic disorder such as MDS

Appendix E: States with Regulations against Redirections in Cancer

State	Step Therapy Prohibited?	Notes
FL	Yes	For stage 4 metastatic cancer and associated conditions.
GA	Yes	For stage 4 metastatic cancer. Redirection does not refer to review of medical necessity or clinical appropriateness.

State	Step Therapy Prohibited?	Notes
IA	Yes	For standard of care stage 4 cancer drug use, supported by peer-reviewed, evidence-based literature, and approved by FDA.
IN	Yes	For advanced, metastatic cancer and associated conditions
LA	Yes [‡]	For stage 4 advanced, metastatic cancer or associated conditions. [‡] Exception if clinically equivalent therapy, contains identical active ingredient(s), and proven to have same efficacy.
MS	Yes	For advanced metastatic cancer and associated conditions
NV	Yes	Stage 3 and stage 4 cancer patients for a prescription drug to treat the cancer or any symptom thereof of the covered person
OH	Yes	For stage 4 metastatic cancer and associated conditions
OK	Yes	For advanced metastatic cancer and associated conditions
PA	Yes	For stage 4 advanced, metastatic cancer
TN	Yes [^]	For stage 4 advanced metastatic cancer, metastatic blood cancer, and associated conditions [^] Exception if step therapy is for AB-rated generic equivalent, interchangeable biological product, or biosimilar product to the equivalent brand drug
TX	Yes	For stage 4 advanced, metastatic cancer and associated conditions

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
MDS	1 tablet (35 mg decitabine/100 mg cedazuridine) PO QD on Days 1 through 5 of each 28-day cycle for a minimum of 4 cycles until disease progression or unacceptable toxicity. A complete or partial response may take longer than 4 cycles.	1 tablet (35 mg decitabine/100 mg cedazuridine)/day
AML	1 tablet (35 mg decitabine/100 mg cedazuridine) PO QD on Days 1 through 5 of each 28-day cycle until disease progression or unacceptable toxicity.	1 tablet (35 mg decitabine/100 mg cedazuridine)/day

VI. Product Availability

Tablet: 35 mg decitabine/100 mg cedazuridine

VII. References

1. Inqovi Prescribing Information. Princeton, NJ: Taiho Pharmaceutical Co., Ltd.; May 2026. Available at www.inqovi.com. Accessed May 27, 2026.
2. Decitabine Prescribing Information. Piscataway, NJ: Camber Pharmaceuticals, Inc.; June 2024. Available at <https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5662c353-05d0-4bd8-87e4-c92ec9ca861e>. Accessed February 4, 2026.
3. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: http://www.nccn.org/professionals/drug_compendium. Accessed May 27, 2026.

4. National Comprehensive Cancer Network Myelodysplastic Syndromes Version 3.2026. Available at: https://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. Accessed February 4, 2026.
5. National Comprehensive Cancer Network Acute Myeloid Leukemia (Age ≥18 years) Version 3.2026. Available at: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf. Accessed May 27, 2026.
6. Garcia-Manero G, Griffiths EA, Steensma DP, et al. Oral cedazuridine/decitabine: a phase 2, pharmacokinetic/pharmacodynamic, randomized, crossover study in MDS and CMML. *Blood*. 2020 Aug 6;136(6):674-683. doi:10.1182/blood.2019004143
7. Garcia-Manero G, McCloskey J, Griffiths EA, et al. Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. *Lancet Haematol*. 2024 Jan;11(1):e15-e26. doi: 10.1016/S2352-3026(23)00338-1.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
2Q 2022 annual review: modified commercial approval duration from length of benefit to “12 months or duration of request, whichever is less”; for decitabine redirection added by-passing of redirection if state regulations do not allow step therapy in certain oncology settings; references reviewed and updated.	02.14.22	05.22
Template changes applied to other diagnoses/indications.	10.03.22	
2Q 2023 annual review: no significant changes; references reviewed and updated.	02.01.23	05.23
2Q 2024 annual review: no significant changes; references reviewed and updated.	01.16.24	05.24
Added Mississippi to Appendix D.	06.05.24	
2Q 2025 annual review: no significant changes; removed reference to brand Dacogen since brand is obsolete; references reviewed and updated.	01.21.25	05.25
Added step therapy bypass for IL HIM per IL HB 5395	06.27.25	
2Q 2026 annual review: extended Medicaid and HIM initial approval duration from 6 months to 12 months for this maintenance medication for a chronic condition; updated Appendix D with revised language and exception for Tennessee and Indiana; references reviewed and updated. Added ICHRA line of business.	03.26.26	05.26
RT4: added criteria for newly approved FDA indication for AML.	04.27.26	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical

policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions, and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment, or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members, and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note:

For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2020 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene[®] and Centene Corporation[®] are registered trademarks exclusively owned by Centene Corporation.